新型コロナウイルス治療薬の特例承認について｜厚生労働省
https://www.mhlw.go.jp/stf/newpage_27695.htmlBundle the HTML, screenshot, summaries, and metadata into one ZIP file. Pro saves automatically start preparing the external RFC 3161 timestamp, and only unfinished records need one more preparation step before download.
新型コロナウイルス治療薬の特例承認について｜厚生労働省
Open the dedicated viewer to inspect the saved page with archive metadata pinned above it.
This is a self-contained HTML copy with CSS and images embedded, so it still renders even if the original page disappears.
The dedicated viewer keeps the original URL and saved timestamp visible while you review the archived HTML.
This page announces the special approval of a COVID-19 therapeutic drug by Japan's Ministry of Health, Labour and Welfare on August 30, 2022. Under the Pharmaceutical Affairs Law, "Evusheld Intramuscular Injection Set" (tixagevimab and cilgavimab) submitted by AstraZeneca was approved. The drug is used for treating SARS-CoV-2 infection and preventing its onset. The application was filed on June 9, 2022, with attached documents available separately.
